Monoclonal antibodies are an exciting theapeutic avenue for hematological cancers, including multiple myeloma (MM). Here, Niels van de Donk, MD, PhD, of VU University Medical Centre, Amsterdam, Netherlands, provides an interesting perspective on the rise of monoclonal antibodies for relapsed/refractory MM, including daratumumab and elotuzumab. He discusses the important role of combination regimens, and how these are expanding response rates and patient survival to the point where they could become the next standard of care for MM. This interview took place at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.
Monoclonal antibodies: the arsenal against R/R MM
